XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies
- Resource Type
- Abstract
- Source
- In
Blood 16 November 2008 112(11):2621-2621 - Subject
- Language
- ISSN
- 0006-4971